Respol

Quick links to important sections

Respol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Respol

What Type of Medicine is Respol?

Respol is a Selective Estrogen Receptor Modulator (SERM), clinically recognized for its role as an antineoplastic agent in targeted hormonal therapy. The core component of Respol is the chemical substance Tamoxifen, which functions as an anti-estrogen used to disrupt the effects of the estrogen hormone. The primary action is rooted in hormonal interference. This medication is a synthetic derivative of triphenylethylene and a non-steroidal agent that provides endocrine modulation. It is categorized as a SERM because it displays tissue-specific modulation, acting as an anti-estrogen by competitively binding to estrogen receptors in certain tissues while exhibiting estrogen-like effects in others.

Composition, Form, and General Therapeutic Purpose

The active ingredient in Respol is Tamoxifen citrate, an oral medication presented either as a tablet or a liquid oral solution. This availability in two distinct forms allows for flexible administration depending on the patient's needs. Pharmacologically, Tamoxifen is a pro-drug that must be metabolized into its highly potent derivatives, such as Endoxifen, to achieve its full therapeutic effect.

The general therapeutic purpose of Respol is derived from its ability to disrupt the signals that stimulate cell proliferation in hormone-sensitive contexts. By achieving estrogen receptor blockade, the medication exerts a cytostatic action, strategically managing conditions that are reliant on the estradiol hormone for growth. A typical use scenario involves its application in preventing the recurrence of certain hormone receptor-positive conditions.

Regulatory References

  1. U.S. National Library of Medicine
  2. National Cancer Institute

What side effects are possible with Respol?

Possible Side Effects and Safety Information

The safety profile of Respol is officially structured by classifying adverse reactions based on how often they occur, as documented by government regulatory agencies.

Frequency-Classified Adverse Reactions

The following side effects are organized by the affected System-Organ-Class and frequency, derived from clinical trials data:

System-Organ-Class Frequency Category Specific Adverse Reactions
Nervous system disorders Very Common Headache
Gastrointestinal disorders Very Common Nausea
Common Diarrhea, Abdominal pain, Vomiting
Nervous system disorders Common Dizziness
General disorders and administration site conditions Uncommon Fatigue

Note on Exposure-Related Patterns: Regulatory documentation states that many adverse reactions, such as those affecting the gastrointestinal system, are typically transient. They often occur most frequently on the first day of treatment and generally resolve within a few days despite continued use.

Safety Restrictions and Considerations

The drug's safety information includes specific restrictions and cautions concerning certain health conditions:

  • Contraindications: Respol is not to be used in individuals with severe hepatic impairment (severe liver disease).
  • Caution for Use: Safety documentation requires particular caution and monitoring for patients with severe, unstable, or clinically relevant pre-existing cardiac conditions. This includes severe heart failure, clinically relevant slow heart rate (bradycardia), and uncontrolled arrhythmias. Use in patients with clinically unstable cardiac conditions (e.g., acute myocardial infarction, unstable angina) is not recommended.

Overdose and Emergency Response

The officially documented descriptions of Respol (Tamoxifen) overdose primarily relate to the toxicities observed following very high or prolonged supratherapeutic exposure. While no specific acute overdose syndrome is defined in regulatory labeling, severe hematologic and metabolic manifestations have been recorded. These include severe thrombocytopenia and leucocytopenia, as well as hypercalcaemia in certain patient populations. High-dose exposure is further associated with severe systemic effects such as convulsions and breathing difficulty.

The most critical, life-threatening outcomes requiring emergency action are linked to the drug’s high-dose toxicity profile. These serious events include stroke, pulmonary embolism, and deep vein thrombosis (DVT), alongside the long-term risk of uterine malignancies.

The regulatory guidance is explicit regarding immediate action: urgent medical attention must be sought for any signs indicative of a thromboembolic event, such as sudden numbness, chest pain, or swelling in the leg. Furthermore, prompt clinical investigation is required for symptoms such as abnormal vaginal bleeding. No specific antidote is known for this medication. Therefore, the official procedure for managing an overdose is strictly symptomatic and supportive treatment, with thorough monitoring required for documented severe hematologic or metabolic changes. The medication is officially contraindicated in children.

Therapeutic Uses of Respol

Respol is a specialized endocrine-modulating therapy that is commonly used to help manage the risk of the condition returning. The therapeutic benefit is realized through managing diseases and symptoms that may be linked to the hormone estrogen for their manifestation.

Respol is commonly used for the long-term management of hormone receptor-positive (ER+) breast cancer across all stages, including early-stage and metastatic disease. The medication is applied in managing symptoms and conditions in clinical settings that involve risk reduction, relief of physical discomfort related to gynecomastia, and addressing reproductive imbalances. The treatment helps support easing the overall symptom load and is relevant for managing recurrence risk for premenopausal and postmenopausal women and male patients, offering supportive relief.

“The central benefit is the long-term management of risk, which may assist with supporting functional stability.”

This therapeutic application helps support easing symptoms related to systemic imbalance, such as pain and tenderness, and assists with supporting functional stability in high-risk contexts. Specifically for postmenopausal women, the therapy is considered relevant for easing symptoms linked to organ-specific functional stress, offering important support for skeletal health during the overall treatment course.


Quick Fact: Supportive Management for Symptoms
This medication is used in situations involving certain distressing symptoms, contributing to improved comfort during periods of heightened symptoms linked to organ-specific functional stress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Respol?

Eligibility to use Respol (Tamoxifen) is strictly defined by regulatory authorities based on population, physiological state, and certain pre-existing conditions.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults, including premenopausal women, postmenopausal women, and men.
Populations for whom use is not recommended Children and adolescents under 18 years of age (safety and efficacy not established).
Populations for whom use is contraindicated Patients with known hypersensitivity to the medicine; pregnant or breastfeeding women.

Eligibility-Related Restrictions

  • Pregnancy and Lactation: Use is contraindicated during pregnancy. Women of childbearing potential must use effective non-hormonal contraception during therapy and for a specified time after cessation.
  • Thromboembolic Risk: Use is contraindicated for breast cancer risk reduction if the patient has a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), or requires Coumarin-type anticoagulants.
  • Organ Function: Use requires caution in patients with pre-existing hepatic impairment, with monitoring advised.

Eligibility Classifications (High-Level)

Category Regulatory Status Terminology (as defined in official documents)
Eligibility severity classification Contraindicated (e.g., Pregnancy, Hypersensitivity), Not Recommended (e.g., Pediatrics), Use with Caution (e.g., Hepatic Impairment).

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by classifying population groups into strict categories: absolute contraindications, conditional restrictions (e.g., liver function), and established adult use. This framework prohibits use in certain high-risk and reproductive states while permitting use in adults with specific conditions only under mandated surveillance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with other products are primarily related to the potential for systemic absorption of the active ingredient. Although Respol is intended for topical application, systemic effects can occur, particularly with prolonged use, high concentrations, or application to large areas of broken skin.

Documented Interaction Mechanisms

Mechanism Interacting Product Category Effect
Thyroid Peroxidase Inhibition Other antithyroid medicines May lead to additive anti-thyroid activity, potentially causing or worsening thyroid dysfunction (e.g., goiter) due to interference with thyroid hormone synthesis.
Decreased Excretion Certain medications that affect renal excretion (e.g., Acetylsalicylic Acid) May increase the serum concentration of the active ingredient, raising the risk of systemic toxicity, including central nervous system effects or methaemoglobinaemia.

General Interaction Advice

Use of topical products containing ingredients known to precipitate proteins (keratolytics) may interfere with the action or stability of other topical medications or preparations applied to the same area. Due to the potential for systemic absorption and anti-thyroid effects, caution is warranted when co-administering with other agents known to affect thyroid function or those that could increase systemic exposure by altering renal clearance. Consultation with a healthcare professional is necessary before combining this with other prescribed or over-the-counter medicines.

Mechanism of Action

How Respol Works

Tissue-Selective Estrogen Receptor Modulation (SERM)

Respol’s mechanism involves its role as a Selective Estrogen Receptor Modulator. Its active form, Endoxifen, competitively binds to the Estrogen Receptors ( ERalpha and ERbeta). This binding induces a unique, tissue-specific conformational change in the receptor that dictates whether the hormone’s transcriptional activity is suppressed (antagonism) or promoted (agonism), thereby modulating cellular activity influenced by the hormone.

Pro-Drug Activation and Metabolic Dependency

The parent compound is a pro-drug that is not fully active until it undergoes biotransformation, primarily via the liver enzyme Cytochrome P450 2D6 ( CYP2 D6), to yield the highly active metabolite Endoxifen. This metabolic conversion is essential because Endoxifen is the highly active metabolite that engages the competitive antagonism necessary for suppressing proliferative signals.

Gene Expression Suppression Cascade

The antagonistic action initiates a gene expression suppression cascade by blocking the recruitment of co-activator proteins to the ER complex in target cells. This molecular interference prevents the transcription of growth-promoting genes, leading to cell cycle arrest in sensitive systems and shapes the resulting alteration of physiological signaling in targeted tissues.

Dosage and Administration Information

How to Use Respol

Respol (Tamoxifen) is administered exclusively through the oral route, available as a tablet or a liquid solution. This use is strictly defined by clinical guidelines concerning dosage, frequency, and duration.

Administration Schedule

The standard prescribed daily dose for most approved conditions, including adjuvant therapy, is 20 mg. For the management of metastatic hormone-sensitive conditions, the approved daily dosing range is 20 mg to 40 mg.

  • Frequency Pattern: The medication is typically taken once daily. If the total daily dose exceeds 20 mg (e.g., 40 mg), the dose must be administered in divided doses, usually taken in the morning and evening.
  • Timing: Respol may be taken with or without food.
  • Duration: For adjuvant use and risk reduction, the treatment course is generally long-term, typically extending for five years.

Procedural Constraints

The correct use of Respol is structured by specific procedural requirements.

Procedural Requirement Constraint
Tablet Integrity Tablets must be swallowed whole and should not be crushed, broken, or chewed.
Liquid Measurement The oral solution must be measured accurately using the dosing device provided with the product.
Missed Dose Do not take a double dose to make up for a forgotten dose; instead, skip the missed dose if it is close to the next scheduled time.
Solution Shelf Life The liquid solution must be discarded three months after the initial opening.

These instructions establish the standardized approach to administering the medicine, defining the correct route, necessary dosage distribution, and required duration of the overall therapy.

Recent Clinical Evidence

Research evidence / Overview of Studies for Respol (Tamoxifen)


Evidence for Hormone Receptor-Positive Early-Stage Breast Cancer (Adjuvant Therapy)

Research on the use of Respol (Tamoxifen) following initial treatment is based on large-scale Randomized Controlled Trials (RCTs) and collaborative Meta-analyses. Respol was studied for its use following initial therapy by monitoring specific outcomes such as the Recurrence-Free Interval and Overall Survival. The populations studied included women who were premenopausal or postmenopausal, as well as some male patients, all with tumors confirmed to be Estrogen Receptor-Positive (ER+).

Major pooled analyses report consistent patterns regarding the outcomes measured for recurrence events and overall survival compared to those who did not receive the medicine. Observed long-term outcomes for women in the 5-year treatment groups were tracked for up to 15 years in some of the largest collaborative study reports.


Evidence for Breast Cancer Risk Reduction (Chemoprevention)

Research focusing on Respol examined the risk of developing breast cancer in high-risk women focuses on research from major Randomized Controlled Trials. The trials examined the Incidence of Invasive Breast Cancer as a key measurement over a five-year treatment period and the subsequent observation phase.

Studies observed patterns related to a measured pattern in the incidence of Estrogen Receptor-Positive (ER+) invasive breast cancer cases when comparing the groups that received the medicine versus those who received a placebo. This pattern was mainly observed for ER-positive types of cancer, but studies reported no measured difference for ER-negative cancers.


Research Gaps and Uncertainties

Despite extensive research, certain limitations exist in the current evidence landscape. Comparative evidence is lacking regarding the long-term outcomes of Respol versus other treatments in premenopausal women, which limits direct comparison in that population. Furthermore, data for certain groups remain insufficient, as the follow-up durations were limited in some trials for specific subgroups. These subgroups include patients with certain rare comorbidities or genetic factors that affect how the medicine is processed by the body.

Key Studies & References

  1. Long-Term Data from 20 Trials Confirm Tamoxifen's Long-Lasting Benefit (Early Breast Cancer Trialists' Collaborative Group)
  2. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24 (DCIS)

Frequently Asked Questions (FAQ)

Common questions about Respol (FAQ)


Q: Does Respol cause long-term side effects that I should know about?

Official regulatory documents indicate that long-term use of Respol, particularly when used for risk reduction, may be associated with certain serious risks. These can include an increased likelihood of conditions such as stroke, pulmonary embolism, specific uterine malignancies (like endometrial cancer), and cataracts. For this reason, a healthcare professional typically monitors the patient throughout the course of therapy.


Q: Is it true that Respol can cause unusual dreams or sleep disturbances?

Official safety summaries from clinical trials report that sleep disturbances are possible with Respol use. Insomnia, which is difficulty falling or staying asleep, is specifically listed as a common adverse reaction. Any persistent sleep issues should be discussed with a healthcare professional.


Q: Are there any clinical trials or studies available that look at Respol's effectiveness?

Yes, the approved uses of Respol are based on the results of large-scale clinical studies and collaborative analyses. Regulatory documents refer to major trials that provided the evidence necessary for its approval. These studies investigated the drug’s effectiveness for adjuvant treatment and risk reduction.


Q: What's the typical duration of treatment with Respol?

The duration of Respol treatment is determined by the specific condition being managed. According to official product information, for adjuvant therapy and risk reduction, the course is typically recommended to last for five years. The actual duration may differ based on individual medical needs and the plan established by a healthcare professional.


Q: How long after stopping Respol do its effects completely wear off?

The medication's half-life determines how long it stays in the body. Respol itself has a half-life of 5 to 7 days, but its highly active metabolite remains in the system for longer, with a half-life of about 14 days. This means it may take several weeks after the final dose for the drug to be entirely cleared from the system.


Q: Is Respol effective for all stages of the condition it's used to treat?

Respol is approved for use in both the adjuvant setting, which is typically for early-stage disease following primary treatment, and for advanced (metastatic) disease. Additionally, it is approved for reducing the risk of invasive breast cancer in high-risk women. Its effectiveness is highly dependent on the condition being hormone receptor-positive.


Q: Is it okay for pregnant or breastfeeding people to use Respol?

Official regulatory information clearly states that Respol is contraindicated, meaning it must not be used, during pregnancy due to the potential for harm to the fetus. Since it is not known if the drug passes into breast milk, official advice states that breastfeeding is not recommended during therapy.


Q: Does Respol have a 'black box' warning, and what does that mean?

Yes, the U.S. FDA label includes a Boxed Warning, often called a 'Black Box' warning, which is reserved for medications associated with serious or life-threatening risks. For Respol, this warning highlights risks like uterine malignancies, stroke, and pulmonary embolism when the drug is used for breast cancer risk reduction.


Q: Can Respol affect the results of common lab tests, such as blood work?

Official safety documents mention the need for routine monitoring of certain laboratory parameters during treatment. This may include regular checks of blood cell counts, liver function tests, and calcium levels. These parameters are monitored to help track a patient's health status during therapy.


Q: Does Respol have a generic version available, and is it the same?

Yes, the active ingredient in Respol, Tamoxifen, is available as a generic medication (Tamoxifen Citrate). Generic versions are required to meet the same official standards for quality and effectiveness as the brand-name product.


Q: Will Respol interfere with birth control pills?

Women of childbearing potential are officially advised to use effective non-hormonal barrier methods of contraception while taking Respol. Hormonal birth control methods, including oral contraceptive pills, are generally not the recommended contraceptive choice during this therapy.


Q: Is Respol a drug that requires a prescription, or can it be bought over the counter?

Respol is a prescription-only medication, often labeled as 'Rx Only,' and cannot be bought over-the-counter. It is only available to patients under the direction and supervision of a licensed healthcare professional.


Q: Can Respol be used safely by people with mild kidney problems?

Official regulatory information states that a dose adjustment for Respol is not typically required for patients with kidney impairment. However, comprehensive studies on chronic dosing in patients with more severe kidney problems are limited.


Q: Are there any warnings about driving or operating machinery while on Respol?

Since Respol has been associated with adverse reactions like dizziness and general fatigue, official warnings note that patients should consider their individual response before driving or operating complex machinery.


Q: Do other medications need a dose adjustment when taken alongside Respol?

Yes, caution is warranted with certain medications. Official drug information notes that drugs which affect the CYP2D6 or CYP3A4 liver enzymes may alter the concentration of Respol’s active metabolite in the blood, potentially requiring a dose consideration.


Q: Is Respol known to cause weight changes (gain or loss)?

According to some official safety summaries, weight gain is reported as a common side effect of Respol. Any changes in weight should be discussed with a healthcare professional.


Q: Are there any known interactions between Respol and alcohol consumption?

Official patient information indicates that while there is no strict prohibition on alcohol, consumption may trigger or worsen hot flashes. Hot flashes are a known and common side effect associated with taking Respol.


Q: What should I do if I experience a mild allergic reaction to Respol?

Official safety warnings indicate that symptoms of a severe allergic reaction, such as swelling of the face, tongue, lips, eyes, or the development of a severe rash, necessitate immediate medical attention.


Q: Does Respol have any known psychoactive properties or effects on mood?

Yes, official safety summaries report that psychiatric adverse reactions are possible with Respol use. Specifically, side effects such as depression and general mood changes have been reported in official documentation.


Q: Are there any specific genetic factors that influence how Respol works?

Yes, official pharmacogenomic data highlights that genetic variations in a liver enzyme called CYP2D6 can influence the drug’s effectiveness. This enzyme is responsible for metabolizing Respol into its highly potent active form, Endoxifen.


Q: Does Respol interact with any herbal supplements like St. John's Wort?

Official drug interaction warnings advise caution with certain herbal products. Specifically, supplements like St. John’s Wort, which are known to affect liver enzymes, should be avoided as they may reduce the required level of the active medicine in the body.


Q: Will Respol make me feel 'groggy' or impair my concentration?

Due to the reported adverse reactions of fatigue (tiredness) and dizziness in clinical trials, there is a potential for Respol to cause feelings of grogginess or affect concentration. Official warnings recommend that patients consider their individual response before driving or operating complex machinery.


Q: What types of patients typically have the best response to Respol treatment?

The medicine is specifically indicated for patients whose condition is dependent on the hormone estrogen. Therefore, the best response is typically seen in patients whose tumors or conditions are confirmed to be Estrogen Receptor-Positive (ER+).


Q: Are there any rare but serious side effects associated with Respol use?

Yes, official warnings and regulatory documents highlight the association of Respol use with rare but serious risks. These risks include the development of life-threatening events such as pulmonary embolism, stroke, and specific types of uterine cancer.


Q: Is Respol considered a type of antibiotic or something else?

No, Respol is not an antibiotic. It is officially classified as an antineoplastic agent used in hormonal therapy. Its pharmacological class is a Selective Estrogen Receptor Modulator (SERM), meaning it works by modulating the effects of estrogen.


Q: If I feel better, is it okay to stop taking Respol before the course is finished?

Regulatory information and standard medical practice advise that the full course of Respol treatment must be completed exactly as prescribed. A change in the duration of treatment, including stopping early, should only be made following consultation with a healthcare provider.


Q: Has Respol been studied in diverse patient populations?

The clinical trials supporting the use of Respol have included adults across different hormonal statuses, specifically premenopausal women, postmenopausal women, and men. However, regulatory documents may note that comparative evidence or long-term follow-up data can be limited for certain demographic or genetic subgroups.

How should Respol be stored and disposed of?

Official Storage Requirements

Respol (Tamoxifen) must be stored according to official regulatory specifications to maintain product integrity. The tablets should be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted transient excursions between 15 C and 30 C.

Condition Requirement
Temperature Restriction Do not store above 30 C and protect from freezing.
Container & Protection Keep in the original container, tightly closed, and protect from light, heat, and moisture.
Child Safety Store the medication out of the sight and reach of children.

Stability and Disposal

Respol Oral Solution, once opened, is stable for 3 months and must be discarded if it appears cloudy or contains foreign particles. Unused or expired Respol must be disposed of in accordance with local official requirements. The medication should not be disposed of via household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Respol found in:

A-Z Index: